

FemSeven Mono, Conti & Sequi Stock Update from Theramex

Updated on 12th November 2019

As Hormonal Replacement Therapy (HRT) shortages continue to impact patients in the UK, we consider it important to update both healthcare professionals and patients on the supply of the FemSeven product range.

Theramex holds the marketing authorisation for FemSeven Mono, FemSeven Conti and FemSeven Sequi in the UK. Theramex acquired these products from Teva Pharmaceutical Industry Ltd on 1st February, 2018

Non patient safety related quality issues with regards to the adhesive, were brought to our attention and as a result, the FemSeven, Conti and Sequi products have been out of stock in the UK since Q4 2018 and FemSeven Mono since September 2019. We have since been working diligently to investigate and fix these issues.

We completely appreciate the distress this is causing for patients who use these products and would like to assure you that we are doing all we can to ensure the issues are resolved as quickly as possible.

As part of this process, Theramex will need to conduct experimental testing to confirm that the products meet the required quality standards. This process can be time consuming, but the efficacy and safety of the medicinal products we provide for our patients is paramount.

We will of course, inform clinics, hospitals and pharmacies when the products are available once again, so that clinicians can make appropriate prescription decisions for their patients. We estimate that this will be Q4 2020 for FemSeven Mono & Conti, and Q1 2021 for FemSeven Sequi.

In the meantime, we recommend that patients consult their doctor, who will be able to advise on the most appropriate HRT alternative options.

Once again, please be assured that we appreciate the impact this is having on patients' lives and are committed to resolving the issues as quickly as we can.

We will of course continue to provide further updates should there be any significant change to the timelines stated above.